Jon Eric Arnason MD

Physician

525 E 68th StFl 3New York, NY 10065
Phone+1 212-746-3481
Fax+1 212-746-6645

Dr. Arnason is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arnason's full profile Already have an account?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2010 - 2027
NY State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014, 2016-2017

Clinical Trials

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
TERMINATED
PHASE2
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
COMPLETED
PHASE2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
RECRUITING
PHASE2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
William G Wierda, Kathleen A Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J Kipps
Blood. 2026-07-28
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
Lara Stepan, Sahar Ansari, Jeremy S Abramson, Abood Okal, Justine Dell'Aringa
Journal of Clinical Oncology. 2026-07-01
A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.
Jennifer L Crombie, Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey
Blood Advances. 2026-06-09

Abstracts/Posters

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma SubtypesMarch 31st, 2023
$Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term Outcomes$
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023